Imris has received clearance from Australia’s Therapeutic Goods Administration (TGA) to market its latest products ImrisNV and Imriscardio. ImrisNV and Imriscardio systems allow the capabilities of both MRI and x-ray angiography in a single suite without the need to transport the patient between modalities.
Imris said that its ImrisNV features a wide bore 3T MR scanner and a bi-plane angiography system completely integrated into a single suite that permits patients being treated for neurovascular disorders to transition quickly and seamlessly between MR imaging and intervention without transporting the patient between modalities.
MR images can be taken before and during procedures to assess tissue health, and can also be used in conjunction with the fluoroscopic images during the interventional procedure. On completion of the procedure, new images can be taken to evaluate the intervention.
Imriscardio provides physicians with enhanced images for visualizing the cardiovascular system before, during and after an intervention. The Imriscardio suite includes a wide bore 1.5T MR scanner and a single-plane or bi-plane angiography system providing the ability to alternate between imaging modalities and immediately assess treatment.
ImrisNV and Imriscardio have been approved for sale in Australia, Canada, the US and Europe and have been selected by leading medical facilities.
Ed Richmond, president and COO of Imris, said: “There is growing demand for innovative image guided solutions that assist clinicians in improving outcomes for patients with neurovascular and cardiovascular disorders. We are pleased to have the opportunity to bring ImrisNV and Imriscardio to Australia with these new regulatory approvals.”